4CPS-086 Comparison of a traditional ELISA technique versus a point-of-care technique in the determination of adalimumab levels in patients with inflammatory bowel disease

Background and ImportanceELISA is the most commonly used technique to determine adalimumab (ADL) levels in patients with inflammatory bowel disease (IBD), as it is simple and inexpensive. Its disadvantage is that it requires a specialised laboratory and several tens of samples have to be accumulated to make the cost of each determination more efficient, with the consequent delay in obtaining the results. Rapid tests make it possible to obtain levels in a very short time (15 minutes) and to act immediately to optimise biological therapy.Aim and ObjectivesThe aim of this study is to compare the reference technique for quantifying ADL levels using ELISA with quantification using a rapid test, the point of care (POC) test.Material and MethodsADL levels of 56 IBD patients were tested by both methods. Samples were obtained prior to ADL infusion. Promonitor®ADLv2 kits from Progenika Biopharma were used for the enzyme-linked immunoassay (ELISA). For the rapid assay (POC), the Quantum Blue® Adalimumab Lateral Flow Immunochromatography technique (BÜHLMANN Laboratories) was used.Quantitative comparison of both techniques was assessed with Bland-Altman plots, Student’s t-test and regression line to test for agreement between the two techniques. A p-value of